3 Keys to Success in the Oncology Care Model

Article

Oncology practices, especially providers participating in value-based reimbursement programs from the Centers for Medicare and Medicaid Services (CMS) like the Oncology Care Model (OCM), are under pressure to measure and improve performance. Three interdependent key factors-technological capabilities, people resources, and visionary leadership-are the shared characteristics of OCM practices best able to maximize program benefits and improve the patient experience. Learn more about each attribute with real-world examples in this whitepaper.

Download Supplement

Sponsored by:

Cota

  • (866) 648-3833

 

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content
Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL

Kristie L. Kahl
December 7th 2025
Article

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

What Benefit Does Zanubrutinib Provide in Relapsed/Refractory CLL/SLL?

Kyle Doherty
December 7th 2025
Article

The CR/CR with incomplete bone marrow recovery rate was 12.8% in patients with relapsed/refractory CLL/SLL following zanubrutinib treatment.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Azacitidine Plus Venetoclax Improves EFS in Acute Myeloid Leukemia

Jonah Feldman
December 7th 2025
Article

Azacitidine plus venetoclax reduced the risk of progressive disease, persistent disease prompting therapy change, relapse, hospice, or death by 45%.

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Epcoritamab Combo Significantly Improves Efficacy in 2L R/R Follicular Lymphoma

Gina Mauro
December 7th 2025
Article

The phase 3 EPCORE FL-1 trial showed that adding epcoritamab to R2 delivered superior PFS and response rates for patients with relapsed/refractory FL vs R2 alone.